The rechallenge with first or second EGFR TKIs to NSCLC patients who acquired the C797S resistance mutation during osimertinib treatment has also been proposed, delaying the use of platinum-based chemotherapy since there is no approved targeted therapeutic strategies in this setting, so far (84). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.